Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Green Reports Positive Results with miRNA-Expressing Potato Plant

Premium

Agbio firm Rosetta Green said this week that it has successfully completed a preliminary study showing that the addition of a specific microRNA could improve the drought tolerance of potato plants.

In the experiment, potato plants expressing a miRNA identified as RGN-131 were found to demonstrate “significantly improved survival and tolerance to drought conditions compared to the control plants,” the company said.

After being subjected to drought, the miRNA-expressing plants and the control plants were irrigated normally, according to Rosetta Green. “Only plants expressing RGN-131 successfully recovered and continued to develop, while the control plants completely wilted and could not continue to grow.”

The miRNA shop said it intends to test the function of RGN-131 in other crops such as wheat, corn, rice, soy, and cotton.

Rosetta Green was spun out of miRNA diagnostics firm Rosetta Genomics in 2008, and became a publicly traded company in Israel earlier this year (GSN 2/24/2011).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.